Meeting
2016 ASCO Annual Meeting
Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma.
Authors
Johnny Duerinck
UZ Brussel, Brussels, Belgium
Johnny Duerinck , Stephanie Du Four , Frank Bouttens , Vincent Verschaeve , Chantal Andre , Frank Van fraeyenhove , Cristo Chaskis , Nicky D'Haene , Marie Le Mercier , Isabelle Salmon , Bart Neyns
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01562197
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2038)
DOI
10.1200/JCO.2016.34.15_suppl.2038
Abstract #
2038
Poster Bd #
226
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.
First Author: Bart Neyns
Poster
2016 ASCO Annual Meeting
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
First Author: Wolfgang Wick
Poster
2014 ASCO Annual Meeting
Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma.
First Author: Bart Neyns
Poster
2013 ASCO Annual Meeting
A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET).
First Author: Kathryn Maree Field